Poolbeg Pharma PLC

AIM:POLB Rapport sur les actions

Capitalisation boursière : UK£41.5m

Poolbeg Pharma Gestion

Gestion contrôle des critères 2/4

We currently do not have sufficient information about the CEO.

Informations clés

Jeremy Skillington

Directeur général

UK£362.0k

Rémunération totale

Pourcentage du salaire du PDG69.1%
Durée du mandat du directeur général3.3yrs
Propriété du PDG0.2%
Durée moyenne d'occupation des postes de directionless than a year
Durée moyenne du mandat des membres du conseil d'administration3.3yrs

Mises à jour récentes de la gestion

Recent updates

Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth

Aug 20
Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Feb 16
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Oct 05
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Jun 01
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Jul 12
Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Analyse de la rémunération des PDG

Comment la rémunération de Jeremy Skillington a-t-elle évolué par rapport aux bénéfices de Poolbeg Pharma?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-UK£4m

Mar 31 2024n/an/a

-UK£4m

Dec 31 2023UK£362kUK£250k

-UK£4m

Sep 30 2023n/an/a

-UK£4m

Jun 30 2023n/an/a

-UK£5m

Mar 31 2023n/an/a

-UK£5m

Dec 31 2022UK£310kUK£250k

-UK£5m

Dec 31 2021UK£261kn/a

-UK£3m

Rémunération vs marché: Jeremy's total compensation ($USD469.79K) is about average for companies of similar size in the UK market ($USD369.71K).

Rémunération et revenus: Jeremy's compensation has increased whilst the company is unprofitable.


PDG

Jeremy Skillington (53 yo)

3.3yrs

Titularisation

UK£362,000

Compensation

Dr. Jeremy Skillington, Ph D., serves as Chief Executive Officer and since July 19, 2021 as Director at Poolbeg Pharma PLC. He is Vice President of Business Development at Inflazome Ltd.Dr. Skillington se...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Cathal Friel
Executive Chairman of The Board3.7yrsUK£150.00k4.36%
£ 1.8m
Jeremy Skillington
CEO & Directorno dataUK£362.00k0.17%
£ 72.5k
Ian O'Connell
CFO & Directorno dataUK£237.00k1.67%
£ 691.1k
Carol Dalton
Vice President of Investor Relations & Public Relations1.8yrspas de donnéespas de données
John McEvoy
Senior Vice President & Chief Legal Officerless than a yearpas de donnéespas de données
David Allmond
Chief Business Officerless than a yearpas de donnéespas de données
Ross Crockett
Group Financial Controllerno datapas de donnéespas de données

0.9yrs

Durée moyenne de l'emploi

53.5yo

Âge moyen

Gestion expérimentée: POLB's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Cathal Friel
Executive Chairman of The Board3.7yrsUK£150.00k4.36%
£ 1.8m
Jeremy Skillington
CEO & Director3.3yrsUK£362.00k0.17%
£ 72.5k
Ian O'Connell
CFO & Director3.5yrsUK£237.00k1.67%
£ 691.1k
Luke O'Neill
Independent Non-Executive Director & Member of Scientific Advisory Board3.3yrsUK£40.00kpas de données
Brendan Buckley
Member of Scientific Advisory Board & Independent Non Executive Director1.9yrsUK£24.00k0.53%
£ 218.4k
Elaine Sullivan
Member of Scientific Advisory Boardno datapas de donnéespas de données
Edward Gibson
Senior Independent Director3.3yrsUK£35.00kpas de données
Daniel Hoft
Member of Scientific Advisory Board3yrspas de donnéespas de données

3.3yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Conseil d'administration expérimenté: POLB's board of directors are considered experienced (3.3 years average tenure).